The journey of canakinumab; on- and off-label indications
The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b se...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2019-05-01
|
| Series: | Beyond Rheumatology |
| Subjects: | |
| Online Access: | https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-1-1-4.pdf |